Sarepta Therapeutics (SRPT) Misses Q2 EPS by 7c, Offers Guidance

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.18), $0.07 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $233.5 million versus the consensus estimate of $220.81 million.

GUIDANCE:

Sarepta Therapeutics sees FY2022 revenue of $905-920 million, versus the consensus of $899.9 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Darden Restaurants (DRI) Reports In-Line Q1 EPS, Misses on Revenue; Offers FY27 EPS Guidance
• Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting